Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel

European Journal of Clinical Pharmacology

Volumn 57, Issue 4, 2001, Pages 305-307

  Malingre M M ^c   Ten Bokkel Huinink, W W ^a   Mackay, M ^b   Schellens, J H M ^c   Beijnen, J H ^c  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b Aventis Pharma BV   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cyclosporin A; Docetaxel; Oral

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; DOCETAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; DOSE RESPONSE; DRUG ABSORPTION; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; TAXOIDS;

EID: 0034896262     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280100315     Document Type: Article

References (19)

1. Cyclosporin A increases the oral bioavailability of docetaxel in mice
2. Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans
3. Cyclosporins as drug resistance modifiers
4. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs
5. Co-administration of cyclosporin A strongly enhances the oral bioavailability of docetaxel
6. Phase I and pharmacokinetic study of oral paclitaxel
7. Relative performance of specific and non-specific fluorescence polarization immunoassay for cyclosporine in transplant patients
8. Noncompartmental analysis based on statistical moment theory
9. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation
10. First-pass metabolism of cyclosporin by the gut
11. Clinically significant drug interactions with cyclosporin
12. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
13. Cyclosporine A monitoring in patients with renal, cardiac and liver transplants: A comparison between fluorescence polarization immunoassay and two different RIA methods
14. Specific monoclonal radioimmunoassay and fluorescence polarization immunoassay for through concentration and area-under-the curve monitoring of cyclosporine in renal transplantation
15. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood
16. Inhibition and induction of cytochrome P450 and the clinical implications
17. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation
18. Cyclosporine-associated chronic nephropaty